Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | CFTR | P13569 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19991850 | 0.93 | ALDH1A1 (0.50) | ALDH1A1HSD17B10CFTRKMT2AMEN1 | |
| SCHEMBL2895994 | 0.86 | ALDH1A1 (0.67) | ALDH1A1HSD17B10CFTRKMT2AMEN1 | |
| SCHEMBL25095928 | 0.83 | KDM4E (0.49) | ALDH1A1HSD17B10CFTRKMT2AMEN1 | |
| SCHEMBL30217815 | 0.83 | KDM4E (0.49) | ALDH1A1HSD17B10CFTRKMT2AMEN1 | |
| SCHEMBL29279663 | 0.81 | TSHR (0.52) | ALDH1A1HSD17B10CFTRKMT2AMEN1 | |
| SCHEMBL31589985 | 0.81 | ALDH1A1 (0.71) | ALDH1A1HSD17B10CFTRKMT2AMEN1 | |
| SCHEMBL505249 | 0.81 | ALDH1A1 (0.71) | ALDH1A1HSD17B10CFTRKMT2AMEN1 | |
| SCHEMBL1188290 | 0.81 | ALDH1A1 (0.60) | ALDH1A1HSD17B10KMT2AMEN1CYP1A2 | |
| SCHEMBL17707767 | 0.81 | NPC1 (0.49) | ALDH1A1HSD17B10KMT2AMEN1CYP1A2 | |
| SCHEMBL23659 | 0.80 | TSHR (0.61) | ALDH1A1HSD17B10CFTRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258314-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2025-03-25 | — | — | US | disclosed |
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-10-08 | — | — | US | disclosed |
| CN-113637005-B | KRAS inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024062363-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS CBL-B INHIBITORS | GLENMARK PHARMACEUTICALS LTD (IN) | 2024-03-28 | — | — | WO | disclosed |
| CN-117756836-A | Heteroaryl compound containing boron, nitrogen and silicon, organic electroluminescent device and display device | 阜阳欣奕华材料科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4090660-B1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-31 | — | — | EP | disclosed |
| US-RE49698-E1 | Substituted dihydroquinazolines | AIC246 AG & CO. KG (DE) | 2023-10-17 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-112673009-B | Substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-1218358-B1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1670768-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006002474-A1 | ALPHA-HELICAL MIMETICS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005037796-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050065160-A1 | Substituted dihydroquinazolines | BAYER HEALTHCARE AG (DE) | 2005-03-24 | — | — | US | disclosed |
| EP-1218358-A1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| US-6399603-B1 | QUINAZOLINES; RETARDING APOPTOSIS IN CELLS; INHIBITING CLEAVAGE OF PROTEIN SUBSTRATES BY CASPASE-3; CHEMICAL AND HYDROLYTIC STABILITY | ASTRAZENECA AB (SE) | 2002-06-04 | — | — | US | disclosed |
| WO-2001021598-A1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| US-6187779-B1 | ADMINISTERING ANTITUMOR AGENTS TO TREAT COLON CANCER | CELL PATHWAYS, INC. | 2001-02-13 | — | — | US | disclosed |
| US-5721238-A | ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258314-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | ALDH1A1 3442/4885HSD17B10 3975/4885CFTR 2871/4885 |
| US-20050065160-A1 | Substituted dihydroquinazolines | TPMT, TYMP, DPYD | ALDH1A1 2784/4885HSD17B10 3738/4885CFTR 2195/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | ALDH1A1 3411/4885HSD17B10 3270/4885CFTR 609/4885 |
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | NR3C1, NR3C2, GRK5 | ALDH1A1 1871/4885HSD17B10 937/4885CFTR 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.